



## **FOR IMMEDIATE RELEASE**

### **Global Media Contacts:**

David Schull or Lena Evans  
Russo Partners  
+1 212-845-4271  
+1 212-845-4262  
david.schull@russopartnersllc.com  
lena.evans@russopartnersllc.com

David Kujawa  
OrbusNeich  
+1 954-730-0711 (office)  
+1 305-733-7216 (mobile)  
dkujawa@orbusneich.com

### **Use of OrbusNeich's Genous™ Stent in a Coronary Bifurcation Setting Is Feasible and Safe, with No Incidence of Late Stent Thrombosis and a Very Low Rate of Repeated Revascularization**

*Data Published in December Issue of  
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine*

HONG KONG, Dec. 20, 2011 – OrbusNeich today reported clinical data showing that the Genous Stent is a feasible and safe option for the treatment of bifurcation lesions, with no incidence of late stent thrombosis (ST) and a very low rate of repeat revascularization reported at one year. The data were published in the December issue of *Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine*.

In the prospective, controlled registry, a total of 43 consecutive patients with 47 consecutive bifurcation lesions were treated with OrbusNeich's endothelial progenitor cell (EPC) capturing Genous Stent. The rate of binary restenosis inside the stent, the study's angiographic endpoint, was 5 percent, with rates of 2.1 percent in the main branch (MB) and 10.5 percent in the side branch (SB). The mean late

lumen loss was  $0.31 \pm 0.4$  mm in the MB and  $0.4 \pm 0.39$  in the SB. No in-hospital, 30-day or 12-month major adverse cardiac events (MACE) were reported.

“Bifurcation lesions remain a challenge because they are prone to higher rates of restenosis and poor immediate outcomes,” said Andrea Rognoni, M.D., of the Azienda Ospedaliero-Universitaria “Maggiore della Carità” di Novara, Italy, and first author of the study. “While drug eluting stents (DES) have improved outcomes in the bifurcation setting, they are still associated with a small but statistically significant increase in late and very late thrombosis. These data show that, in addition to good clinical and angiographic results, the use of Genous resulted in no late stent thrombosis at one-year follow-up. As a result, we believe that Genous is a feasible and safe alternative to DES in this high-risk scenario. We are also planning to report four-year follow-up data from this study early in 2012.”

Patients eligible for the study included those with stable or unstable angina pectoris, non-ST elevation myocardial infarction, silent ischemia and *de novo* coronary bifurcations lesions. Of the coronary bifurcations treated, 24 involved the left anterior descendent – diagonal branch bifurcation, 17 involved the left circumflex-obtuse marginal branch and six involved the posterior descendent artery-posterior lateral. All parameters were calculated five mm proximal and distal to the stented segments, with angiographic follow-up performed seven to eight months after PCI using the CMS-Medis Medical Imaging System.

### **About the Genous Technology**

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents

and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

### **About OrbusNeich**

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit [www.OrbusNeich.com](http://www.OrbusNeich.com).

Follow OrbusNeich on Twitter at [www.twitter.com/OrbusNeich](http://www.twitter.com/OrbusNeich), and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel: <http://www.youtube.com/user/OrbusNeichMedia>.

###